Search Results - "Ian Robins, H"

Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature by Tipping, Matthew, Eickhoff, Jens, Ian Robins, H.

“…•Bevacizumab (BEV) is a common treatment for recurrent glioblastoma (r-GBM).•Post BEV survival (OS) & progression free survival (PFS) are not well…”
Get full text

A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320 by Sperduto, Paul W., MD, MPP, Wang, Meihua, PhD, Robins, H. Ian, MD, PhD, Schell, Michael C., PhD, Werner-Wasik, Maria, MD, Komaki, Ritsuko, MD, Souhami, Luis, MD, Buyyounouski, Mark K., MD, Khuntia, Deepak, MD, Demas, William, MD, Shah, Sunjay A., MD, Nedzi, Lucien A., MD, Perry, Gad, MD, Suh, John H., MD, Mehta, Minesh P., MD

“…Background A phase 3 Radiation Therapy Oncology Group (RTOG) study subset analysis demonstrated improved overall survival (OS) with the addition of…”
Get full text

Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab by Magnuson, William, Ian Robins, H., Mohindra, Pranshu, Howard, Steven

“…Outcomes after bevacizumab failure for recurrent glioblastoma (GBM) are poor. Our analysis of 16 phase II trials ( n  = 995) revealed a median overall survival…”
Get full text

Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients by Vera-Bolanos, Elizabeth, Aldape, Kenneth, Yuan, Ying, Wu, Jimin, Wani, Khalida, Necesito-Reyes, Mary Jo, Colman, Howard, Dhall, Girish, Lieberman, Frank S, Metellus, Philippe, Mikkelsen, Tom, Omuro, Antonio, Partap, Sonia, Prados, Michael, Robins, H Ian, Soffietti, Riccardo, Wu, Jing, Gilbert, Mark R, Armstrong, Terri S

“…Ependymomas are rare CNS tumors. Previous studies describing the clinical course of ependymoma patients were restricted to small sample sizes, often with…”
Get full text

Management of leptomeningeal metastases: Prognostic factors and associated outcomes by Brower, Jeffrey V, Saha, Sandeep, Rosenberg, Stephen A, Hullett, Craig R, Ian Robins, H

“…Highlights • Leptomeningeal metastases represent a rare complication of systemic malignant disease. • In this setting, outcomes have historically been…”
Get full text

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study by DE GROOT, John F, LAMBORN, Kathleen R, MEHTA, Minesh P, LASSMAN, Andrew B, DEANGELIS, Lisa M, YUNG, W. K. Alfred, CHEN, Alice, PRADOS, Michael D, WEN, Patrick Y, CHANG, Susan M, GILBERT, Mark R, CLOUGHESY, Timothy F, ALDAPE, Kenneth, JUN YAO, JACKSON, Edward F, LIEBERMAN, Frank, ROBINS, H. Ian

“…Antivascular endothelial growth factor (anti-VEGF) therapy is a promising treatment approach for patients with recurrent glioblastoma. This single-arm phase II…”
Get full text

An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway by Guo, Deliang, Reinitz, Felicia, Youssef, Mary, Hong, Cynthia, Nathanson, David, Akhavan, David, Kuga, Daisuke, Amzajerdi, Ali Nael, Soto, Horacio, Zhu, Shaojun, Babic, Ivan, Tanaka, Kazuhiro, Dang, Julie, Iwanami, Akio, Gini, Beatrice, Dejesus, Jason, Lisiero, Dominique D, Huang, Tiffany T, Prins, Robert M, Wen, Patrick Y, Robins, H Ian, Prados, Michael D, Deangelis, Lisa M, Mellinghoff, Ingo K, Mehta, Minesh P, James, C David, Chakravarti, Arnab, Cloughesy, Timothy F, Tontonoz, Peter, Mischel, Paul S

“…Glioblastoma (GBM) is the most common malignant primary brain tumor of adults and one of the most lethal of all cancers. Epidermal growth factor receptor…”
Get more information

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors by Vivanco, Igor, Robins, H Ian, Rohle, Daniel, Campos, Carl, Grommes, Christian, Nghiemphu, Phioanh Leia, Kubek, Sara, Oldrini, Barbara, Chheda, Milan G, Yannuzzi, Nicolas, Tao, Hui, Zhu, Shaojun, Iwanami, Akio, Kuga, Daisuke, Dang, Julie, Pedraza, Alicia, Brennan, Cameron W, Heguy, Adriana, Liau, Linda M, Lieberman, Frank, Yung, W K Alfred, Gilbert, Mark R, Reardon, David A, Drappatz, Jan, Wen, Patrick Y, Lamborn, Kathleen R, Chang, Susan M, Prados, Michael D, Fine, Howard A, Horvath, Steve, Wu, Nian, Lassman, Andrew B, DeAngelis, Lisa M, Yong, William H, Kuhn, John G, Mischel, Paul S, Mehta, Minesh P, Cloughesy, Timothy F, Mellinghoff, Ingo K

“…Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs through mutations or deletions in the extracellular (EC) domain. Unlike…”
Get more information

RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients by Chakravarti, Arnab, MD, Wang, Meihua, PhD, Robins, H. Ian, MD, PhD, Lautenschlaeger, Tim, MD, Curran, Walter J., MD, FACR, Brachman, David G., MD, Schultz, Christopher J., MD, Choucair, Ali, MD, Dolled-Filhart, Marisa, MD, Christiansen, Jason, MD, Gustavson, Mark, MD, Molinaro, Annette, MA, PhD, Mischel, Paul, MD, Dicker, Adam P., MD, PhD, Bredel, Markus, MD, PhD, Mehta, Minesh, MD

“…Purpose To determine the safety and efficacy of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with radiation…”
Get full text

Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825 by Patil, Nirav, Somasundaram, Eashwar, Waite, Kristin A., Lathia, Justin D., Machtay, Mitchell, Gilbert, Mark R., Connor, James R., Rubin, Joshua B., Berens, Michael E., Buerki, Robin A., Choi, Serah, Sloan, Andrew E., Penas-Prado, Marta, Ashby, Lynn S., Blumenthal, Deborah T., Werner-Wasik, Maria, Hunter, Grant K., Flickinger, John C., Wendland, Merideth M., Panet-Raymond, Valerie, Robins, H. Ian, Pugh, Stephanie L., Mehta, Minesh P., Barnholtz-Sloan, Jill S.

“…Background/purpose Glioblastoma (GBM) is the most common primary malignant brain tumor. Sex has been shown to be an important prognostic factor for GBM. The…”
Get full text

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas by Lamborn, Kathleen R, Yung, W K Alfred, Chang, Susan M, Wen, Patrick Y, Cloughesy, Timothy F, DeAngelis, Lisa M, Robins, H Ian, Lieberman, Frank S, Fine, Howard A, Fink, Karen L, Junck, Larry, Abrey, Lauren, Gilbert, Mark R, Mehta, Minesh, Kuhn, John G, Aldape, Kenneth D, Hibberts, Janelle, Peterson, Pamela M, Prados, Michael D

“…The North American Brain Tumor Consortium (NABTC) uses 6-month progression-free survival (6moPFS) as the efficacy end point of therapy trials for adult…”
Get full text

Case report: Radiographic complete response of radiation-induced glioblastoma to front-line radiotherapy: A report and molecular characterization of two unique cases by Grogan, Patrick T, Helgager, Jeffrey J, Deming, Dustin A, Howard, Steven P, Jenkins, Robert B, Robins, H Ian

“…Radiation-induced gliomas (RIGs) are an uncommon disease type and a known long-term complication of prior central nervous system radiation exposure, often…”
Get full text

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02 by Lee, Eudocia Q, Kuhn, John, Lamborn, Kathleen R, Abrey, Lauren, DeAngelis, Lisa M, Lieberman, Frank, Robins, H Ian, Chang, Susan M, Yung, W K Alfred, Drappatz, Jan, Mehta, Minesh P, Levin, Victor A, Aldape, Kenneth, Dancey, Janet E, Wright, John J, Prados, Michael D, Cloughesy, Timothy F, Gilbert, Mark R, Wen, Patrick Y

“…The activity of single-agent targeted molecular therapies in glioblastoma has been limited to date. The North American Brain Tumor Consortium examined the…”
Get full text

Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study by CLOUGHESY, Timothy F, WEN, Patrick Y, LIEBERMAN, Frank, KUHN, John, DEANGELIS, Lisa M, MEHTA, Minesh, RAIZER, Jeff J, ALFRED YUNG, W. K, ALDAPE, Ken, WRIGHT, John, LAMBORN, Kathleen R, PRADOS, Michael D, IAN ROBINS, H, CHANG, Susan M, GROVES, Morris D, FINK, Karen L, JUNCK, Larry, SCHIFF, David, ABREY, Lauren, GILBERT, Mark R

“…A phase II study was undertaken in patients with recurrent malignant glioma to determine the efficacy and safety of tipifarnib, a farnesyltransferase…”
Get full text

[124I]CLR1404 PET/CT in High-Grade Primary and Metastatic Brain Tumors by Hall, Lance T., Titz, Benjamin, Baidya, Nishanta, van der Kolk, Anja G., Robins, H. Ian, Otto, Mario, Perlman, Scott B., Weichert, Jamey P., Kuo, John S.

“…Purpose There is a continuous search for imaging techniques with high sensitivity and specificity for brain tumors. Positron emission tomography (PET) imaging…”
Get full text

A Phase III Study of Conventional Radiation Therapy Plus Thalidomide Versus Conventional Radiation Therapy for Multiple Brain Metastases (RTOG 0118) by Knisely, Jonathan P.S., M.D., F.R.C.P.C, Berkey, Brian, M.S, Chakravarti, Arnab, M.D, Yung, Al W.K., M.D, Curran, Walter J., M.D, Robins, H. Ian, M.D., Ph.D, Movsas, Benjamin, M.D, Brachman, David G., M.D, Henderson, Randall H., M.D., M.B.A, Mehta, Minesh P., M.D

“…Purpose To compare whole-brain radiation therapy (WBRT) with WBRT combined with thalidomide for patients with brain metastases not amenable to resection or…”
Get full text

Reirradiation of Large-Volume Recurrent Glioma With Pulsed Reduced-Dose-Rate Radiotherapy by Adkison, Jarrod B., M.D, Tomé, Wolfgang, Ph.D, Seo, Songwon, M.S, Richards, Gregory M., M.D, Robins, H. Ian, M.D., Ph.D, Rassmussen, Karl, B.S, Welsh, James S., M.S., M.D, Mahler, Peter A., M.D., Ph.D, Howard, Steven P., M.D., Ph.D

“…Purpose Pulsed reduced-dose-rate radiotherapy (PRDR) is a reirradiation technique that reduces the effective dose rate and increases the treatment time,…”
Get full text

Phase 1/2 Trials of Temozolomide, Motexafin Gadolinium, and 60-Gy Fractionated Radiation for Newly Diagnosed Supratentorial Glioblastoma Multiforme: Final Results of RTOG 0513 by Brachman, David G., MD, Pugh, Stephanie L., PhD, Ashby, Lynn S., MD, Thomas, Theresa A., MS, Dunbar, Erin M., MD, Narayan, Samir, MD, Robins, H. Ian, MD, PhD, Bovi, Joseph A., MD, Rockhill, Jason K., MD, PhD, Won, Minhee, MA, Curran, Walter P., MD

“…Purpose The purpose of phase 1 was to determine the maximum tolerated dose (MTD) of motexafin gadolinium (MGd) given concurrently with temozolomide (TMZ) and…”
Get full text

Histological Predictors of Outcome in Ependymoma are Dependent on Anatomic Site Within the Central Nervous System by Raghunathan, Aditya, Wani, Khalida, Armstrong, Terri S., Vera-Bolanos, Elizabeth, Fouladi, Maryam, Gilbertson, Richard, Gajjar, Amar, Goldman, Stewart, Lehman, Norman L., Metellus, Phillipe, Mikkelsen, Tom, Necesito-Reyes, Mary Jo T., Omuro, Antonio, Packer, Roger J., Partap, Sonia, Pollack, Ian F., Prados, Michael D., Robins, H. Ian, Soffietti, Riccardo, Wu, Jing, Miller, C. Ryan, Gilbert, Mark R., Aldape, Kenneth D.

“…Ependymomas originate in posterior fossa (PF), supratentorial (ST) or spinal cord (SC) compartments. At present, grading schemes are applied independent of…”
Get full text

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08) by Wen, Patrick Y, Yung, W K Alfred, Lamborn, Kathleen R, Norden, Andrew D, Cloughesy, Timothy F, Abrey, Lauren E, Fine, Howard A, Chang, Susan M, Robins, H Ian, Fink, Karen, Deangelis, Lisa M, Mehta, Minesh, Di Tomaso, Emmanuelle, Drappatz, Jan, Kesari, Santosh, Ligon, Keith L, Aldape, Ken, Jain, Rakesh K, Stiles, Charles D, Egorin, Merrill J, Prados, Michael D

“…Platelet-derived growth factor (PDGF) and its receptors (PDGFR) are frequently coexpressed in meningiomas, potentially contributing to their pathogenesis. The…”
Get full text